Sai Life Sciences · NSE: SAILIFE · BSE: 544306
Q4 FY25 results · Jan–Mar 2025
Sai Life Sciences reported revenue from operations of ₹579.51 crore and net profit of ₹88.27 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 579.51 | — | — | 439.78 | +31.8% |
| Other income | 9.60 | — | — | 9.12 | +5.3% |
| Total income | 589.11 | — | — | 448.89 | +31.2% |
| Profit before tax | 118.80 | — | — | 71.65 | +65.8% |
| Net profit for the period | 88.27 | — | — | 53.85 | +63.9% |
| EPS, basic (₹) | 4.24 | — | — | 2.89 | +46.7% |
| Net margin (%) | 15.2 | — | 12.2 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 567.01 | — | — | 428.60 | +32.3% |
| Other income | 9.82 | — | — | 9.45 | +3.9% |
| Total income | 576.83 | — | — | 438.05 | +31.7% |
| Profit before tax | 120.47 | — | — | 67.91 | +77.4% |
| Net profit for the period | 89.94 | — | — | 51.06 | +76.1% |
| EPS, basic (₹) | 4.32 | — | — | 2.74 | +57.7% |
| Net margin (%) | 15.9 | — | 11.9 |
Consolidated
- Filed with BSE
- 14 May 2025, 19:09 IST
- Board meeting
- 13 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 May 2025, 19:09 IST
- Board meeting
- 13 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE